For a patient with end‑stage renal disease on chronic dialysis presenting with acute coronary syndrome, can ticagrelor be used and what is the appropriate dosing regimen?

Ticagrelor Use in ESRD Patients on Dialysis with ACS

Ticagrelor can be used in dialysis patients with acute coronary syndrome at standard dosing (180 mg loading dose, 90 mg twice daily maintenance), as no dose adjustment is required based on pharmacokinetic studies, though current evidence suggests clopidogrel may be the safer choice in this population.

Dosing and Pharmacokinetics

Ticagrelor requires no dose adjustment in hemodialysis patients 1. A dedicated pharmacokinetic study demonstrated that hemodialysis resulted in only modestly higher exposure to ticagrelor and its active metabolite (AR-C124910XX), with no clinically significant effect on platelet inhibition or tolerability 1. The timing of hemodialysis relative to ticagrelor administration has minimal impact on drug levels or antiplatelet effect 1.

Standard dosing per guidelines:

• Loading dose: 180 mg orally 2
• Maintenance: 90 mg twice daily 2, 3
• Use with low-dose aspirin (75-100 mg daily) 2

Critical Safety Considerations

Evidence Favoring Clopidogrel Over Ticagrelor

The most recent meta-analysis (2023) comparing ticagrelor versus clopidogrel specifically in dialysis patients with ACS found that ticagrelor was associated with significantly higher risks 4:

• Increased major adverse cardiovascular events (MACE)
• Increased all-cause mortality
• Increased major bleeding events

This finding is corroborated by a 2023 systematic review showing no significant efficacy advantage of ticagrelor over clopidogrel in dialysis patients, with similar bleeding rates between the two agents 5.

Contradictory Evidence in Non-Dialysis Advanced CKD

Importantly, studies in patients with severe CKD (GFR <30 ml/min) not on dialysis show different results. In this population, ticagrelor/prasugrel demonstrated:

• Lower 1-year mortality in STEMI patients 6
• Reduced MACE and stroke 7, 8
• No increase in major bleeding 8

This creates a critical distinction: The dialysis population appears to respond differently than advanced CKD patients not yet on dialysis.

Clinical Algorithm for Decision-Making

For ESRD patients on chronic dialysis with ACS:

1. First-line recommendation: Clopidogrel (300-600 mg loading, 75 mg daily maintenance) 4

   • Lower mortality risk
   • Lower MACE
   • Lower major bleeding compared to ticagrelor in dialysis-specific studies

2. Consider ticagrelor (standard dosing) if:

   • Patient has documented clopidogrel resistance or prior treatment failure
   • Specific high-risk features warrant more potent P2Y12 inhibition
   • Monitor closely for bleeding complications

3. Prasugrel may be considered based on observational data showing reduced mortality and coronary revascularization versus clopidogrel in dialysis patients 9, though this requires careful patient selection given bleeding risks

Common Pitfalls to Avoid

• Do not reduce ticagrelor dose based on dialysis status—pharmacokinetic data does not support this 1
• Do not use aspirin >100 mg daily with ticagrelor, as post-hoc PLATO analysis showed worse outcomes with higher aspirin doses 2
• Do not assume equivalence between dialysis and non-dialysis CKD populations—the evidence diverges significantly
• Recognize the narrow therapeutic window in dialysis patients, who face both extremely high ischemic and bleeding risks simultaneously 10

Guideline Context

Current ACC/AHA guidelines (2025) recommend ticagrelor as Class I for STEMI managed with primary PCI 2, but these guidelines do not specifically address the dialysis population, which was largely excluded from the pivotal PLATO trial. The ESC guidelines (2021) similarly recommend ticagrelor broadly but note contraindications in patients with renal failure requiring dialysis or eGFR <15 ml/min 3.

The evidence hierarchy here prioritizes the dialysis-specific meta-analyses 4, 5 over general ACS guidelines that did not adequately study this population.